GSK 070Alternative Names: GSK 070
Latest Information Update: 07 Jul 2016
At a glance
- Originator Anacor Pharmaceuticals
- Developer Anacor Pharmaceuticals; GlaxoSmithKline; Global Alliance for TB Drug Development
- Class Antituberculars
- Mechanism of Action Leucyl-tRNA synthetase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Tuberculosis